Evidence map›Paper›PMID 41002586›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

A Retrospective Study on Prognostic Factors and Systemic Treatments of Refractory Meningiomas.

Dan-Thanh Christine Nguyen, Cyril Nader, Karl Bélanger, Sarah Lapointe, Bernard Lemieux, Émilie Lemieux-Blanchard, Jean-Paul Bahary, Laura Masucci, Carole Lambert, David Roberge and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dan-Thanh Christine NguyenDepartment of Hematology-Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada.ORCID 0009-0000-1447-5195
Cyril NaderDepartment of Anesthesia, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada.
Karl BélangerDepartment of Hematology-Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada.
Sarah LapointeDepartment of Hematology-Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada.ORCID 0000-0002-7363-7382
Bernard LemieuxDepartment of Hematology-Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada.
Émilie Lemieux-BlanchardDepartment of Hematology-Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada.
Jean-Paul BaharyDepartment of Radio-Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada.
Laura MasucciDepartment of Radio-Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada.
Carole LambertDepartment of Radio-Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada.
David RobergeDepartment of Radio-Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada.ORCID 0000-0001-8747-648X
Robert MoumdjianDepartment of Neurosurgery, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada.
Moujahed LabidiDepartment of Neurosurgery, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada.
Romain CayrolDepartment of Pathology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada.ORCID 0000-0003-2745-2704
Marie FlorescuDepartment of Hematology-Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 1R6, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Standard systemic treatment has not been established for refractory meningioma. This retrospective study aimed to identify prognostic factors for overall survival and document outcomes of systemic therapies. We reviewed patients with meningioma followed at CHUM hospital between 2006 and 2022. Only patients with progression after first-line treatment were included. Among 750 patients, 107 (14%) experienced progression after first-line treatment. They were divided into two groups: Group 1 (

Indexed as

Meningeal NeoplasmsMeningiomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRetrospective Studiesbevacizumabmeningiomaprognostic factorsystemic treatments

Identifiers

PMID41002586
PMCPMC12468139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.